"Hormone receptor-positive (HR+) breast cancer accounts for 75% of all breast cancer diagnoses, and endocrine therapies represent the mainstay of treatment for patients with HR+ breast cancer, in both adjuvant and metastatic settings1. Yet, the efficacy of standard endocrine therapies is limited by primary or acquired resistance2. Periodic fasting enhances the efficacy of endocrine therapies against HR+ breast cancer and delays acquired therapy resistance in animal models3."
"We previously reported that fasting enhances the efficacy of endocrine therapies in HR+ breast cancer3. However, the mechanisms that underlie this effect remain unknown. Moreover, adjuvant endocrine regimens involve five to ten years of continuous daily treatment8, making prolonged combined dietary intervention during endocrine therapy highly challenging to adhere to. Here we investigated the biological mechanisms at the basis of fasting enhancement of tamoxifen (TMX) efficacy, one of the most commonly utilized endocrine therapies, with the aim of identifying therapeutic strategies that phenocopy beneficial effects"
Hormone receptor–positive breast cancer constitutes about 75% of diagnoses, and endocrine therapies are the primary treatments in adjuvant and metastatic settings. Standard endocrine therapies are limited by primary or acquired resistance. Water-only fasting and fasting-mimicking diets (FMDs) reproduce metabolic effects of fasting and have shown feasibility and safety across multiple tumour types. Periodic fasting enhances endocrine therapy efficacy and delays acquired resistance in animal models. Adjuvant endocrine regimens commonly require five to ten years of continuous daily treatment, limiting feasibility of prolonged dietary interventions. Weekly cycles of 48-hour fasting synergize with tamoxifen in MCF7 xenograft mice. Multiomic analyses were performed to define fasting-induced tumour changes.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]